神经损伤与功能重建2018，Vol.13Issue(4)：177-180,4.DOI:10.16780/j.cnki.sjssgncj.2018.04.005
视神经脊髓炎谱系疾病临床特点分析及治疗进展
Clinical Characteristics Analysis and Treatment Progression of Neuromyelitis Optica Spectrum Disorders
摘要
Abstract
Objective: To investigate the clinical characteristics and treatment progression of neuromyelitis optica spectrum disorders(NMOSD). Methods: The clinical manifestations, auxiliary examination results, treatment,and prognosis of 13 NMOSD patients were retrospectively analyzed.Results:The proportion of men to women in the 13 NMOSD cases was 1:3.3,and the average age was(45±14)years.There were 11 cases of acute myelitis,9 cases of optic neuritis,2 cases of area postrema syndrome,2 cases of pruritus,and 3 cases of spastic pain in limbs.There were 9 cases positive for AQP4-IgG in blood and/or cerebrospinal fluid,and of the 3 cases negative for antibody,1 was MOG-IgG positive.MRI showed demyelinating signal with intensification in the long segment of the spinal cord in 11 cases, abnormal signals on the dorsum of the medulla in 1 case, and optic nerve abnormal signals with strengthening in 1 case. Most patients in acute stage were given high-dose corticosteroid, immunoglobulin, or plasma exchange treatment, and some patients received azathioprine in prevention of recurrence. Eleven patients (84.6% ) showed improvement, 1 patient (7.7% ) showed no improvement, and 1 patient (7.7%) showed spontaneous improvement. Eight patients (61.5%) had a course of recurrence, and 5 patients (38.5%) had a monophasic course. Conclusion: The clinical manifestations of NMOSD are varied.Beside the typical core symptoms,there are also many atypical symptoms.Current treatment during the acute phase includes high-dose glucocorticoid, plasma exchange, and immunoglobulin therapy. Azathioprine,mycophenolate mofetil,and rituximab are first-line drugs for prevention.关键词
视神经脊髓炎谱系疾病/临床特点/治疗Key words
neuromyelitis optica spectrum disorders/clinical characteristics/treatment分类
医药卫生引用本文复制引用
赵莹莹,张依,梁文野,徐慧珍,李尧,王瑞金,张拥波..视神经脊髓炎谱系疾病临床特点分析及治疗进展[J].神经损伤与功能重建,2018,13(4):177-180,4.基金项目
国家自然科学基金(No.8167050067) （No.8167050067）
